New 'Smart' immune cells take on kidney cancer in early trial
NCT ID NCT07564232
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial is testing a new treatment called LNK001 for people with advanced or metastatic clear cell renal cell carcinoma (a type of kidney cancer) that has not responded to standard treatments. LNK001 is a type of immunotherapy where a patient's own immune cells are modified to better recognize and attack cancer cells. The study will first find the safest dose and then see if it can help control the disease in 40 participants.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
LNK001 (a type of CAR T cell therapy that targets two proteins on cancer cells)
What this could lead to
If it works, this could provide a new treatment option for advanced kidney cancer that has stopped responding to standard therapies.
What could go wrong
This is an early phase 1 trial with only 40 participants, so it may not work or could have serious side effects. CAR T therapy can cause severe immune reactions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLEAR CELL RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
UT MD Anderson
Houston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact